GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

Strona główna・Stock List・BioArctic AB

B
BioArctic AB

Closed

284.6 -2.47

Buy Sell

Overview

Share price change

24h

Current

Min

284.2

Max

285.2

Key metrics
By Trading Economics
Income	-896M 179M
Sales	-897M 392M
P/E Sector Avg	23.701 35.69
EPS	1.09
Profit margin	45.668
Employees	119
EBITDA	-893M 188M

Market Stats
By TradingEconomics
Market Cap	4.5B 25B
Previous open	287.07
Previous close	284.6

BioArctic AB Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 wrz 2025, 18:25 UTC

Major Market Movers

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

27 wrz 2025, 07:00 UTC

Earnings

This Water Stock Is Dehydrated. What Could Bring It Back. -- Barrons.com

27 wrz 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26 wrz 2025, 21:56 UTC

Acquisitions, Mergers, Takeovers

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26 wrz 2025, 20:54 UTC

Earnings

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26 wrz 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 wrz 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26 wrz 2025, 20:27 UTC

Acquisitions, Mergers, Takeovers

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 wrz 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26 wrz 2025, 19:54 UTC

Market Talk

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26 wrz 2025, 19:53 UTC

Acquisitions, Mergers, Takeovers

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 wrz 2025, 19:40 UTC

Earnings

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26 wrz 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26 wrz 2025, 19:17 UTC

Market Talk

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26 wrz 2025, 19:15 UTC

Market Talk

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26 wrz 2025, 19:03 UTC

Market Talk

Global Equities Roundup: Market Talk

26 wrz 2025, 19:03 UTC

Market Talk

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26 wrz 2025, 18:50 UTC

Market Talk

Earnings

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26 wrz 2025, 18:36 UTC

Market Talk

Silver Closes Out Week With Strong Surge -- Market Talk

26 wrz 2025, 18:02 UTC

Acquisitions, Mergers, Takeovers

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26 wrz 2025, 18:02 UTC

Acquisitions, Mergers, Takeovers

ING: Global Development Hasn't Received All Necessary Approvals >ING

26 wrz 2025, 18:02 UTC

Acquisitions, Mergers, Takeovers

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26 wrz 2025, 17:54 UTC

Market Talk

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26 wrz 2025, 16:56 UTC

Market Talk

Earnings

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26 wrz 2025, 16:41 UTC

Market Talk

Earnings

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26 wrz 2025, 16:26 UTC

Earnings

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26 wrz 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

26 wrz 2025, 16:12 UTC

Market Talk

Nike Stock Seen With Limited Upside -- Market Talk

26 wrz 2025, 15:59 UTC

Market Talk

Global Equities Roundup: Market Talk

26 wrz 2025, 15:59 UTC

Market Talk

Nike Seen Showing Progress in Turnaround -- Market Talk

Peer Comparison

Price change

BioArctic AB Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.